Hailiang Hu

Assistant Professor

Duke University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Hailiang Hu is an Assistant Professor at Duke University, USA. His research focuses on prostate cancer mechanisms, including the modulation of TDO2-Kyn-AhR signalling, therapeutic resistance, and cellular metabolism. He has published articles examining various aspects of cancer biology, such as the role of mitochondrial dysfunction in neurodegenerative diseases and the impact of specific co-transporters on tumor progression.

Articles (12)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (1)

Xia Gao

Baylor College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hailiang Hu

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

AR to GR switch modulates differential TDO2-Kyn-AhR signalling to promote the survival and recurrence of treatment-induced dormant cells in prostate cancer

Bacterial reverse transcriptase synthesizes long poly-A-rich cDNA for anti-phage defense

CHCHD2 rescues the mitochondrial dysfunction in iPSC-derived neurons from patient with Mohr-Tranebjaerg syndrome

Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.

YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer.

A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m<sup>6</sup>A reader YTHDC1.

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer

A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.

N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells.

Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer

A potential therapeutic strategy for prostatic disease by targeting the oral microbiome.

Collaborators (1)

Xia Gao

Make your next move.